Daily index of UK government & Parliament publications
Analysis of 10 key publications
The Trade Remedies Authority has recommended a new anti-dumping measure against Chinese imports of rutile titanium dioxide, citing an imminent threat to UK manufacturers. The TRA found that imports from China have risen dramatically—volumes in May 2026 reached 299 per cent of May 2025 levels—driven by expanded Chinese production capacity and trade barriers erected elsewhere. Rutile titanium dioxide is a critical industrial input used as a whitening agent across coatings, plastics, paper and consumer products. The measure reflects the government's post-Brexit trade enforcement strategy, targeting what it characterises as unfair competitive practices by foreign suppliers.
Prime Minister Andy Burnham issued a statement commemorating the October 7th attacks on Israel, pivoting to address what he called a "disturbing rise" in antisemitic behaviour across the UK. He cited the October 2025 terrorist attack on Manchester's Heaton Park Hebrew Congregation alongside other subsequent assaults on Jewish people and institutions, signalling that community protection has become a security priority. The government is funding protection for synagogues, schools and community buildings, with Burnham pledging zero tolerance for "abuse and violence" whether "on our streets, not online, not in our schools or universities". The statement also reaffirmed Britain's commitment to a two-state solution abroad.
The Serious Fraud Office confirmed it will not pursue retrials following a Supreme Court judgment that quashed convictions in the LIBOR manipulation cases—a decision that marks a dramatic reversal for one of modern finance's most significant prosecutions. The SFO had secured nine convictions of senior bankers for fraud offences relating to the rigging of benchmark interest rates affecting hundreds of trillions of dollars in financial products globally, including ordinary people's pensions and mortgages. The court found that judicial directions to juries in the Hayes and Palombo trials were incorrect, rendering those convictions unsafe. While the SFO's decision not to seek retrials spares the public further expense, it underscores how legal standards on fraud prosecutions have tightened considerably since the investigations began in 2013.
The Attorney General, Ellie Reeves KC, has opened applications for a new Director of the Serious Fraud Office, framing the role as central to the government's economic crime agenda. Reeves emphasised that financial crime poses a growing threat to prosperity and national security, risking the UK's international reputation as a safe place to conduct business. The successful candidate will lead a multi-disciplinary organisation responsible for investigating and prosecuting the most serious fraud, bribery and corruption cases, alongside close coordination with law enforcement partners and international agencies. The appointment comes at a moment of considerable pressure on the institution, following the Supreme Court's demolition of its LIBOR convictions.
The Competition and Markets Authority has decided to accept remedies offered by Co-operative Group in its acquisition of Southern Co-operative, averting a costly phase-two investigation into the supermarket merger. The CMA had initially determined in September that the deal posed a substantial lessening of competition risk, triggering the threat of an in-depth referral unless undertakings were offered. The parties have now proposed acceptable concessions to address these concerns, allowing the merger to proceed under conditions the regulator deems sufficient to protect market competition. Details of the specific remedies remain limited in the available materials, but the outcome represents a pragmatic resolution in an increasingly consolidated grocery sector.
The Medicines and Healthcare Products Regulatory Agency has approved catumaxomab—marketed as Korjuny—to treat malignant ascites, a painful accumulation of cancer-cell-containing fluid in the abdomen that often requires repeated drainage procedures. The monoclonal antibody works by targeting a protein called EpCAM on cancer cell surfaces and activating the immune system to destroy them, extending the interval between drainage procedures for patients when standard cancer treatment is no longer viable. The MHRA noted that malignant ascites can impose considerable burden on terminally or severely ill patients, and this approval offers a meaningful therapeutic option where alternatives are exhausted. The regulator will maintain ongoing safety and effectiveness monitoring as with all licensed medicines.
Scheduled publications from NHS England on referral-to-treatment waiting times for consultant-led elective care, A&E performance metrics, and cancer patient waiting times for August and September 2026 appear in today's announcement schedules but lack substantive content in available materials. These datasets will provide the monthly granularity by which the government and opposition track the health service's performance against manifesto commitments and prior-year baselines. Given ongoing staffing pressures and industrial action within the NHS, such figures typically receive considerable scrutiny on both sides of Parliament.